JAL Therapeutics is currently seeking $3M - $5M in seed funding to complete preclinical research (safety, PK, PD, toxicology & CMC) for its lead drug candidate JAL-001 to treat Alzheimer’s disease (AD). This will set the stage for an IND application and first human clinical trials. The company has developed a patented, small molecule drug platform of highly selective butyrylcholinesterase (BChE) inhibitors. JAL-001 demonstrates a potent 68,000-fold selectivity over acetylcholinesterase (AChE) and is designed to restore the neurotransmitter acetylcholine to normal levels without side effects.
The pivotal challenges in emerging therapies, such as gene therapy, CAR-T/stem cell therapy, immunotherapy, and regenerative medicine, include daunting characterization, manufacturing, and chemistry (CMC), poor quality control (QC), costs, and biosafety. The CLE technology harnesses a paradigm-shifting approach by chemically, physically blebbing desired cells to produce cell-like vesicles that fully replicate the structure and function of the parent cells. The CLE technology achieves significantly higher yield in a substantially shorter time via incredibly simpler concentration and purification processes than conventional extracellular vesicle (EV) method, resulting homogeneous, stable, and economically competitive products. Additionally, all types of cells are subject to the CLE technology with consistently high efficiency.
Recent developments in cancer research have discovered drugs that block kinase pathways that spur cancer growth, and agents that activate the immune system to eradicate tumors. These approaches have revolutionized the treatment of cancer, but are effective in less than half the cases. A critical step in the progression of tumors is when cancer cells gain the ability to metastasize. Here we have developed a class of small molecules that can block two critical steps in metastasis- the movement of cancer cells and thier ability to recruit blood and lymphatic vessels. These therapies could be used to inhibit metastasis of a broad variety of cancer types, with proof of concept data provided for melanoma.
At least half of the US adult population is predicted to have obesity by 2030. While new drugs are coming to market and even more are in the pipeline, they focus on satiety without doing anything to treat the root causes of metabolic disease. Siege’s compounds act through a novel mitochondrial mechanism to not only induce weight loss but also directly address drivers of obesity’s lethal co-morbidities including type 2 diabetes, fatty liver disease, cardiovascular disease, and chronic kidney disease. Templated off of natural molecules, our compounds hit a unique constellation of targets to safely and effectively treat multiple facets of metabolic disease. These same targets have been validated in cancer, where we have shown that daily administration reduces growth of an autochtonous prostate cancer model by 82%.
Tumor margin detection is difficult in head and neck and breast procedures, inadequate resection yields local recurrence, and broad resections are morbid procedure DOCI technology allows the detection of tumor margins without the need for injecting fluorescing material. Currently, there is no validated intraoperative technology to help surgeons identify precise cancer margins. There is a significant gap in the areas of intraoperative cancer margin delineation and precise surgical treatment of head and neck and breast cancer patients. We have developed a solution for this unmet clinical need.
The Bio-Zipper has been developed to improve post-surgical patient outcomes and reduce the frequency of surgical complications following lower urinary tract reconstructive surgeries. Current standard-of-care closures have high complication rates (30-day range from 30-68%), and are limited by surgeon experience with the technology (e.g., robotics) and the complexity of the procedure. Staples or adhesives are currently unavailable alternatives for the urinary tract, as they fail to adhere in moist conditions and/or increase the risk of infections, wound breakdown, or stone formation. There are currently 680,000 annual urologic reconstructions performed in the U.S. which would be the initial market for this device. Within this context, the Bio-Zipper has been designed to reinforce suture lines in these complex surgical reconstructions. By doing so, it will decrease 30-day complications (with a mean hospital cost of nearly $30,000 per incidence) by 20%. This will result in a mean savings of $5,600 per procedure.
(Note: No company is formed yet. Seeking entrepreneur to lead.) An alternative approach to treatment of AD and other neurodegenerative diseases is to target aberrant pathogenic calcium signaling cascades. Stabilization of calcium signaling targets a pathogenic mechanism that is tied to many major features and risk factors of Neurodegenerative diseases. Compounds and methods for treating neurological diseases by normalizing neuronal calcium dyshomeostasis.
BioSpecimen Technologies (BST) is a medical device development company with revolutionary patented technologies that greatly improve the quality of patient blood testing in clinical labs, hospitals and RNA/DNA research and testing centers.
The Future of Performance Fabrics IS Thermoregulation. What is Revolutionary here? In the sixties, waterproof-breathable membranes forever changed how we think about rainwear. In the nineties, we learned that polyester was superior to cotton in athletic wear, spawning a new age of fitness apparel. The next BIG THING will be THERMOREGULATORY materials – and they’ll revolutionize the industry.
The Medical College of Wisconsin Office of Technology Development (MCW’s “Tech Transfer Office”) seeks an experienced biotechnology leader to start a new company, license gene therapy IP described below, raise the funding needed and to bring one or more products to Phase I clinical testing. The ideal candidate will have experience with the earliest stages of gene therapy (or other complex biologic) product development and testing. They would understand how to develop a plan, raise funding (whether SBIR, Angel, VC), work with investors, build an effective team and engage with CROs.
GW researchers developed a cell therapy manufacturing platform that avoids genetic engineering and activates immune cells against multiple, patient-specific target antigens simultaneously. A sample of a patient’s cancer cells obtained by surgery or biopsy is treated with photothermal therapy (PTT) in vitro, delivered by Prussian blue nanoparticles (PBNPs) at an immunogenic thermal dose. Immune cells (e.g. T cells, NK cells) from the patient are then exposed to the PBNP-PTT-treated cancer cells in vitro to activate them against multiple patient-specific, tumor antigens. The activated immune cells are then re-infused to the patient. Preliminary ex vivo data and studies in xenograft animal models show superior specificity of T cells generated through this novel immuno-engineered platform against glioblastoma, over T cells generated through traditional methods.
Fusion energy is the ultimate source of clean energy that produces neither nuclear waste nor greenhouse gases. Existing approaches to inertial fusion power production rely on complex and expensive fusion targets as well as laser systems. GPG Energy enables drastic simplification of the inertial nuclear fusion powerplant, making fusion energy more affordable and bringing it closer to fruition and commercialization.
[Update (8.2023): SBIR/STTR funding total - $7M, NIH Contract - $5.2M] LignaMed is dedicated to developing breakthrough treatments for severe asthma, organ transplant viability, and fibrosis. Its lead drug compound, LGM1506, is a single isomer synthetic small molecule with a unique mechanism of action proven to Improve asthma based on statistically significant data from its completed phase II NIH grant. The company is on track to achieve key inflection points for two of its programs: severe Asthma, with Phase I studies in man possible in 2024 and ex vivo lung perfusion for human donor lungs, with potential market approval under a drug as device pathway in 2024.
Cardiotoxicity of pharmaceutical drugs, industrial chemicals, and environmental toxicants can be severe, even life threatening, which necessitates a thorough evaluation of human response to chemical compounds. Predicting risks for arrhythmia and sudden cardiac death accurately is critical for defining safety profiles. Currently available approaches have limitations including a focus on single select ion channels, the use of non-human species in vitro and in vivo, and limited direct physiological translation. CardiacTEEM has developed in vitro 3D models of atrial and ventricular tissues from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes that can be used to evaluate chamber-specific responses without the need for animals. This self-assembled 3D microtissue technology provides a straightforward way to analyze physiologically relevant metrics like action potential patterns. CardiacTEEM is exploring applications in pharmaceutical development as well as environmental chemical toxicity testing.
The prevalence of chronic pain is currently on the rise, however, there are few effective and accessible cognitive-behavioral interventions that are widely available to the population experiencing chronic pain. Limited healthcare system capabilities and high treatment costs prevent many patients from receiving or even seeking non-pharmaceutical care. Therefore, there is a need for a more accessible, affordable, and efficacious technology that will allow individuals with acute or chronic pain to track and manage their pain symptoms and triggers. The SOMA Pain Manager is a smartphone application that allows acute and chronic pain patients to track and predict pain. Further, a digital therapeutic program is currently being integrated into the application that will deliver cognitive-behavioral interventions. Overall, the SOMA app provides an easy and accessible option for individuals seeking to manage and treat their pain symptoms.
Udacity’s proven playbook is globally scalable, addressing the widespread digital talent shortages that impact growth, productivity, and innovation. We collaborate with enterprises and highly motivated individuals to design a tailored talent transformation journey enabled by our Digital Competency Platform. Our exclusive content is co-created and continually refined with industry leaders. Each Udacity program is deeply focused—eliminating guesswork in selecting the right course. Projects go far beyond step-by-step guides, cultivating the critical thinking required for workplace relevance. Expert mentors unblock learning with personalized support, and verify complete mastery of competencies.
The platform provides individual lessons that employ The StepWise Virtual Tutor that uses A.I. technology that simulates an expert teacher or tutor and is available 24/7.
Real time capture of microscope video that is digitized, formatted and stored for AI and ML based use to enhance patient diagnosis.
Enables any device to download a lightweight software agent of less than 200 lines of code, which can create encryption keys in partnership with any other device. The keys are computationally secure, one-time use and zero trust. TRL: 9
Founded in 2018 at the Georgia Institute of Technology, ThinkLive! is a vibrant blend of education and music, offering STEM education through the medium of turntabling. This unique platform is built by a collective of passionate educators, STEM professionals, and music enthusiasts, aiming to foster intellectual curiosity, socioemotional functioning, and an enduring love for STEM among students. By leveraging youth culture and music, ThinkLive! creates interactive teaching strategies that resonate with diverse learners.
Leveraging proprietary hardware and the quantum mechanics properties of photons to enable quantum communications. Quantum-secure networking leverages the physical-encryption of photons to enable unprecedented sensitivity and speed of detecting eavesdroppers/hackers. Several barriers exist to broad implementation of scalable quantum networking in the real-world. Foremost, devices supporting quantum transactions, analogous to digital telecom, need to be invented. These devices must be deployable in the real-world and, ideally, also compatible with existing infrastructure, like optical fiber beds.
When atoms are cooled to a few millionths of a degree above absolute zero, they take on quantum properties. Lasers are used to arrange the atoms, hold them in place, run computations on them, and read out the results. Quantum calculations, communications, and sensing are the result. This quantum technology can be used to solve some of the world’s most challenging problems.
Drug discovery and development is complicated, time-consuming and costly. Immunai’s computational approach and experimental apparatus is focused on understanding core pathways and mechanisms within each immune cell compartment, and the intersection of these compartments to comprehensively examine disease etiology, and how to reverse it. MIT Startup Exchange / Harvard
Familial adenomatous polyposis (FAP) is a hereditary disease that affects ~50,000 families in the United States and causes the development of hundreds to thousands of adenomas in the rectum and colon. When left untreated, 100% of FAP patients develop colorectal cancer by the age of 45. Although small molecules and monoclonal antibodies targeting mTOR and IL-23 are be tested to treat FAP, these approaches are not specific to polyps and therefore cause a variety of unintended side-effects. Additionally, although genetics studies have identified variants in the APC gene as the causal mutation for FAP, gene therapy technologies need to be optimized to achieve the precision and efficacy necessary to serve as a viable therapeutic option for FAP. This technology is a monoclonal antibody targeting the Annexin A1 (ANXA1) protein complex that may be useful in treating FAP and other cancers related to ANXA1 activity.
Haystack Medical is developing microneedles that allow drug delivery into the inner ear. Over 30M US patients need a way to diagnose and treat inner ear disorders - a number that will only grow as the population ages. To date, we've proven Haystack microneedles to be safe, effective, and minimally invasive in guinea pig and human cadaver studies. Our technology is supported by 20+ peer reviewed papers and multiple granted and pending patents. Our team (Aykut Aksit, PhD, Anil Lalwani, MD; Jeffrey Kysar, PhD) has spent a decade developing this technology at Columbia University combining our experience in otolaryngology and surgery as well as in mechanical engineering and materials science.
Using machine learning and neuroscience, Invictus BCI has created an affordable prosthetic control interface that has a greater movement capability and is more comfortable. Developer of a brain-controlled interface technology intended to create prosthetic control interfaces that can restore near natural functionality. The company's technology leverages new advances in machine learning and neuroscience to create a prosthetic control interface that has more intuitive control, greater movement capability, enabling patients to get access to greater comfort all while being far less expensive. TE
[Update (8.2023): The company raised $1.03 million of convertible debt financing on November 11, 2022] Utilizing artificial intelligence in conjunction with the electrocardiogram to help clinicians identify cardiovascular disease more quickly, more accurately, and at a fraction of the cost.
Talent acquisition agency that utilizes artificial intelligence to create pre-employment assessments for effective skill-to-work matching. Glider AI provides customers with the Glider AI suite tools that hires qualified talent on technical and non-technical levels, combating hiring deception during the interview process. They are most known for their assessment software. This is an AI program that evaluates tech and non-tech skills, and measures behavioral and cognitive characteristics in applicants.
Build and manage a curated set of courses that allow medical practitioners to find professional training in almost all areas of healthcare. Employs sophisticated software to validate a medical provider's knowledge/skill, ensuring that consistent care is achieved. They are most well known for Jane, a machine learning program that measures clinicians ability and knowledge to create an education plan for work competency.
Founded in 2012, DataRobot is an AI Cloud leader with a vision to deliver a unified platform for all users, data types, and environments to accelerate delivery of AI to production for every organization. They help their customers turn data into value using their AI Cloud platform combined with an AI native strategic success team. The AI Cloud platform allows for continuous collaboration in an environment built for optimization.
Freelance deep learning developers and data scientists creating technical projects and participating in hack-a-thons. Projects include a Medical Gateway Platform to connect medical devices and platforms with real time, secure, and private data. A Health Data Labeling System that helps medical companies integrate new data from smart devices. The software collects, cleans, and labels the data. Finally, a Synthetic NF1 which is a method to solve the MRI data shortage in the field of neurofibromatosis type I.
Entelechy’s business-focused approach ensures they design, develop, and deliver the most effective performance change possible. Whether it’s world-class training, job aids, documentation, coaching, consulting, web-based training, or user help, the solution you get from Entelechy is guaranteed to help you achieve your business goals. They provide a training module with training materials and access to a team of learning and development, and instructional design experts to help execute your program flawlessly.
Trivie is a SaaS company that offers an on-demand gamification platform to improve knowledge retention for employees. The platform employs retrieval practice, micro-learning, and adaptive learning that help companies considerably reduce training costs, increase sales, and provide better customer service.
Platform to assess current state and provide personalized intervention where needed. Founded in 2018, QuantHub provides an efficient yet rigorous vetting platform for hiring data professionals and a modern, in the flow of work, learning platform focused on both AI skills for analytics teams and data literacy skills for the entire enterprise. QuantHub is a SaaS subscription-based platform written for data scientists by data scientists, providing skill tests, data challenges, and skill development plans completely tailored to the unique characteristics of the advanced analytics space.
Techniques for detecting infection by monitoring physiological states before symptoms become apparent. A machine learning model is used to analyze patient data and help to identify whether a patient was exposed to an infectious chemical agent. This detection could lead to earlier patient care and increase the probability of a positive prognosis.
[Update (8.2023): SBIR/STTR funding total - $222k, Venture funding total - $3.98M] Prediction Health is revolutionizing patient care and enhancing the efficiency of clinicians and administrators. Designed specifically for Physical Therapy (PT) compliance and documentation, 'PT Practice Intel' simplifies documentation, compliance, and operational excellence. By reading and analyzing free form notes and EHR data, it automates the laborious tasks, reducing burnout, and increasing efficiency, hence fostering a better environment for outstanding patient care.
Innerworld offers a safe, immersive virtual platform designed to enhance patient engagement and facilitate the exploration of emotions and behaviors. Through our interactive therapy world, users learn life-changing Cognitive Behavioral Immersion™ (CBI) tools. Our aim is to help users navigate their mental health journey and progressively move towards actual social interaction.
[Update (8.2023): physIQ has raised a total of $27.09M in funding through 8 funding rounds]. physIQ has created wearable sensors for continuous, remote patient monitoring to provide predictive insights. The platform gives clinicians 24/7 access to provide treatment and care through virtual or hospital-at-home models, it helps to avoid hospital re-admissions by altering the team to life-threatening events in advance, and helps patients take charge of their own care to improve disease management.
[Update (7.2023) SBIR/STTR funding total: $1.3M] Sibel Health revolutionizes patient care with their bio-integrated, wearable sensors such as the ANNE® Chest Sensor, ANNE® Limb Sensor, and ADAM Sensor. These devices offer clinical-grade monitoring and transmit real-time data for comprehensive clinical care. They measure parameters such as heart rate, respiratory rate, temperature, activity, SpO2 pulse rate, and perfusion index. The wearables are lightweight, flexible, and invisible to wear, making healthcare monitoring both comfortable and efficient. They offer dedicated solutions for adult, maternal, and neonatal monitoring, and specific medical conditions, transforming patient data management.
Utilizing artificial intelligence in conjunction with the electrocardiogram to help clinicians identify cardiovascular disease more quickly, more accurately, and at a fraction of the cost. Real time capture of microscope video that is digitized, formatted and stored for AI and ML based use to enhance patient diagnosis. ViewsML uses a machine-learning model to predict biomarker expression in patient samples, both spatially and quantitatively. This reduces a 24+ hour process down to a few seconds, saving time and resources that can be redeployed elsewhere in the hospital or laboratory.
Utilizes a lightweight algorithm and machine learning collected for 8 variables during the first 48 hours of hospitalization to predict the risk of 6-month mortality. Researchers at the University of Minnesota have developed a lightweight algorithm using machine learning for predicting the risk of 6-month mortality at the time of hospital admission. Using just 8 different variables collected during the first 48 hours of hospitalization, this algorithm predicted death within 6-months with an AUC of 0.92. The discriminative ability of this algorithm has been shown to be significantly better than historical estimates of clinician performance. This algorithm can be a critical tool in supporting clinical decision-making at admission and in evaluating suitable options such as transfer to tertiary referral center, serious illness care-conversations in high-risk patients, patient/family counseling, and palliative care utilization.
Industry-leading analytic for predicting all hospital-caused deterioration and sepsis. eCART continually monitors patients using real-time data and drives clinical workflows for front-line staff and rapid response teams to prevent failure to rescue. AgileMD eCART is dedicated to improving patient outcomes by leveraging the way data is used. They are part of a revolutionary change in the delivery of healthcare that is being driven by the rapid uptake in technologies related to the capture, storage, and analysis of data. They empower electronic health records to deliver standardized clinical pathways that recommend orders, document decision-making, and save time.
Comfortable cloth nanotechnology undergarment captures from a patient at home more than 85 medical biomarkers that can be monitored by medical staff remotely. (University of Arkansas)
Araqev uses machine learning to create software solutions for closed-loop, smart control in additive manufacturing. Araqev’s patented machine learning algorithms enable users to design and print new shapes and processes with greater accuracy, resulting in less wasted scrap and machining time.
The company boasts the world’s most advanced molecular AI platform that combines 3D structure-aware deep neural networks, new molecular simulation methods, and a massively scalable molecular generation engine.
The company’s proprietary AtomNet technology identifies new small molecules for therapeutic targeting of difficult proteins. Atomwise is a venture-backed drug discovery platform company powered by robust and evolving machine learning algorithms. The proprietary AtomNet technology identifies new small molecules for therapeutic targeting of difficult proteins. Atomwise has wholly-owned pre-clinical assets in immunology, co-developed assets in oncology, hematology, and immunology, as well as several stealth candidates in discovery phase. (University of Toronto)
Individual genomic testing to provide personalized medicine to improve behavioral health. Focusing on PTSD, they provide insight for those living with the condition and promote further research and discovery.
[Update (8.2023): The company raised $6 million through a combination of Seed 3, and Seed 4 funding on February 14, 2023] Integrating proprietary technologies, the GutLab, “smart bathroom” technology for continuous patient microbiome tracking & MetaBiome, a cloud-based bioinformatics platform. Novel tools to continuously track, analyze, and store individual microbiome profiles, providing vastly more data than, and at a fraction of the cost of, current practice. Creating the GutLab, a novel “smart bathroom” technology for continuous, at-home microbiome tracking & MetaBiome, a cloud-based bioinformatics platform. This platform is a generational leap over existing measurement tools: (1) much cheaper and more scalable, (2) produces & analyze dense time-series data, unlocking an entire dimension of never-before-accessible biomarkers, and (3) has far higher accuracy & precision, ensuring all data generated can be stored in a single, standardized database – a first for the microbiome field.